Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone

Nautilus Biotechnology, Inc.

2025-Q2 EPS reported -$0.25

Operating expenses $17.1M, down 18% YoY from $20.8M.
Net loss $15.0M improved from $18.0M loss in Q2 2024.
Cash, equivalents and investments $179.5M as of June 30, 2025.
Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.
Signed two collaborations to study Tau proteoforms in Alzheimer's disease.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.